Erratum
The authors would like to issue an erratum for this article [1], and would like to declare the following competing interests which we inadvertently failed to include in our original publication. The authors would like to apologise for this omission.
Competing interests
Dr. Salvatore Cuzzocrea, researcher on the study team, is co-inventor on patent WO2013121449 A8 (Epitech Group SpA) which deals with compositions and methods for the modulation of amidases capable of hydrolysing N-acylethanolamines useable in the therapy of inflammatory diseases. Moreover, Dr. Cuzzocrea is also a co-inventor with Epitech group on the following patents:
EP 2 821 083
MI2014 A001495
102015000067344
No other authors have competing interests.
Ethics approval and consent to participate
The study [1] was approved by the University of Messina Animal Care Review Board: protocol number 8/U-apr 16.
Footnotes
The online version of the original article can be found under doi:10.1186/s12974-014-0136-0.
Reference
- 1.Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, Cuzzocrea S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation. 2014;11:136. doi: 10.1186/s12974-014-0136-0. [DOI] [PMC free article] [PubMed] [Google Scholar]